Across TCGA pan-cancer cohorts, KRTAP17-1 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of KRTAP17-1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where KRTAP17-1 RNA is repressed in tumor relative to normal tissue. In most cancer types KRTAP17-1 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

KIRC, KICH, and BRCA are the cancer types where KRTAP17-1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KRTAP17-1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	−0.260	<.001	11	view →
KICH	Male	All	−0.450	<.001	6	view →
BRCA	Female	All	+0.048	.016	4	view →
LUSC	All	All	+0.248	.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: KRTAP17-1 RNA expression & survival · all KRTAP17-1 data types